Loading clinical trials...
Loading clinical trials...
A Phase I Study of 90Y-BC8-DOTA Monoclonal Antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma
Conditions
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation
Cyclosporine
+5 more
Locations
1
United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
January 9, 2012
Primary Completion Date
June 6, 2017
Completion Date
December 6, 2019
Last Updated
December 9, 2019
NCT06356571
NCT05334069
NCT05312255
NCT04508790
NCT04876248
NCT04640779
Lead Sponsor
Fred Hutchinson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions